Rising Leukemia and Lymphoma Cases Boost CAR T Cell Therapy Market, with Positive Phase III Trials Expanding Treatment Potential
The global CAR T cell therapy market is likely to be worth USD 4.6 billion in 2024, and is projected to reach worth USD 25 billion by 2035, growing at a CAGR of 16.6% during the period 2024-2035.
The new research study consists of industry trends, detailed market analysis, funding and investments analysis, and clinical trial analysis. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the CAR T cell therapy market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.
Cancer is one of the leading causes of deaths, globally. In fact, as per World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on the affected individuals, their families, communities as well as the national health systems., Presently, there are several conventional approaches, including chemotherapy, radiation therapy and surgery that are used for the treatment of various cancers. However, among the several treatment options that are available to control disease progression and prevent malignant cells from spreading throughout the body, lasting remission is still difficult to achieve.
In order to mitigate the existing challenges related with the conventional treatment approaches, various active initiatives have been undertaken to develop more targeted anti-cancer therapies; of these, CAR T cell therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Immunotherapies essentially make the use of body’s own immune system, or its components, to fight against cancer. Over the years, different classes of immunotherapies have emerged as an alternative for the management and treatment of cancer; these include therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors and certain whole cell-based therapies (adoptive cell therapies).
CAR-T cell therapy, which is a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant pharmacological success with targeted antibody-based therapeutics, including monoclonal and conjugated antibodies. Overall, this highly specific and promising form of cell therapy, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Moreover, the ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipeline of the companies in this domain. Given the consistent increase in number of CAR T cell therapies being developed and launched, the CAR T cell therapy market is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.
CAR T Cell Therapy Market Share Insights
The CAR T cell therapy market report presents an in-depth analysis of various CAR T cell therapy companies in this domain, across different segments, as defined below:
- Historical Trend: 2018-2023
- Base Year: 2023
- Forecast Period: 2024-2035
- Market Size by 2035: $25 Billion
- CAGR: 16.6%
- Target Indication
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Generalized Myasthenia Gravis
- Hodgkin's Lymphoma
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Ovarian Cancer
- Renal Cell Carcinoma
- Others
- Target Antigen
- CD19
- BCMA
- CD19 / CD22
- Others
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and North Africa
- Rest of the World
- Key CAR T Cell Therapy Companies Profiled
- Alaunos Therapeutics
- Autolus
- Abelzeta Pharma
- Bluebird Bio
- Bristol Myers Squibb
- Carsgen Therapeutics
- Cellectis
- Gilead Sciences
- Innovative Cellular Therapeutics
- Kuur Therapeutics
- Noile-Immune Biotech
- Novartis
- Shanghai GeneChem
- Sinobioway Cell Therapy
- Takara Bio
- Wellington Zhaotai Therapies
- (Full list of more than 250 CAR-T cell therapy companies captured in the market landscape analysis of the report)
- PowerPoint Presentation (Complimentary)
- Customization Scope: 15% Free Customization
- Excel Data Packs (Complimentary)
- Market Landscape
- Clinical Trial Analysis
- Funding and Investments Analysis
- Partnerships and Collaborations
- Patent Analysis
- Market Forecast and Opportunity Analysis
CAR T Cell Therapy Market Segmentation Overview
Market Share by Target Indication
This section segments the CAR T cell therapy market across different target indications, including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, generalized myasthenia gravis, Hodgkin's lymphoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, renal cell carcinoma and others. Non-Hodgkin's Lymphoma holds the maximum share (more than 85%) in the current CAR T cell therapy market and is likely to dominate the market in the future as well. This can be attributed to the rapidly increasing incidence of non-Hodgkin's Lymphoma which make it the 11th most commonly diagnosed cancer globally. Further, the market for CAR-T therapies intended for the treatment of multiple myeloma is estimated to grow at an annualized rate of (CAGR 25%) during the forecasted period.
Market Share by Target Antigen
The global CAR T cell therapy market is segmented into CD19, BCMA, CD19 / CD22 and others. Owing to the success of CD19 targeting therapies (Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel)), the segment for CD19 is likely to capture the highest CAR T cell therapy market share (~70%) as compared to other target antigens in the coming years.
Market Share by Key Geographical Regions
This segment highlights the distribution of CAR T cell therapy market across key geographical regions, including North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World. It is worth highlighting that North America captures more than 40% of the current CAR T cell therapies market. Further, the market for CAR T therapies in Asia-Pacific is expected to grow at an annualized rate (CAGR 23%), during the forecasted period.
Car T Cell Therapy Market Key Insights
The market report features an extensive study of the current market landscape, market size, market share, market analysis, market forecast and future opportunities for the CAR T cell therapy companies. The CAR T-cell therapy market report highlights the efforts of several drug developers engaged in this rapidly emerging market segment of the pharmaceutical industry. Key takeaways of market research report is briefly discussed below.
Pipeline Analysis: 800+ CAR T Cell Therapy Programs in Clinical Trials
With more than 800 therapy programs in the clinical phases of development, CAR-T cell therapies have already established a strong foothold in the overall pharmaceutical industry. Further, close to 300 therapies targeting oncological disorders are in the early (pre-clinical and discovery phase) stages of development. CAR T cell therapy companies are developing therapies against several novel targets that have been analyzed in this research report. The expected launch of several promising leads over the forecast period will drive the CAR T cell therapy market growth.
An in-depth analysis of the pipeline shows that close to 10 CAR-T cell therapies have been commercialized for targeting various cancer indications. At present, of the approved CAR T cell therapies, six have been approved for several hematological malignancies in the US; these are Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™) and Ciltacabtagene Autoleucel (CARVYKTI™). The currently approved candidates target the CD19 receptor and BCMA.
Competitive Landscape of CAR-T Therapy Developers
The CAR-T cell therapy is among the most promising domains in the healthcare industry. Currently, over 190 CAR T cell therapy companies are involved in developing potential treatment options for oncological, non-oncological and other disorders. Additionally, players such as CARgen Therapeutics and Kite Pharma (a Gilead Sciences company) are revolutionizing CAR-T therapies manufacturing, driving impactful advancements in healthcare. In January 2024, Kite Pharma achieves a milestone with the FDA's approval of their advancement in manufacturing process for axicabtagene ciloleucel (Yescarta®), significantly eliminating the median turnaround time.
CAR T Cell Therapy Market Trends Analysis: Increase in Funding, Patents, Partnership and Clinical Trials Activity Reflect the Rising Interest in this Industry
The rising interest of the stakeholders in this domain can be attributed to the increasing strategic alliances that have been by for the development of CAR T cell therapies over the past few years. More than 260 partnerships and collaborations have been inked between several industry / academic stakeholders in order to expedite the development of various pipeline candidates. To fund CAR-T cell therapy development, capital investments worth more than USD 32 billion have been made by various private and public sector investors, in the last few years. Additionally, over 10,000 patents related to CAR T cell therapies have been recently filed / granted, demonstrating the continued innovation in CAR T cell therapy market.
It is worth noting that there has been a notable rise in the number of clinical trials evaluating CAR-T cell therapies. Around 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, indicating substantial research in this domain. Among these, close to 60% of these clinical trials are actively recruiting patients to evaluate drugs for various types of oncology, non-oncological and other disorders. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR T cell therapy market size is likely to witness significant growth during the forecast period.
Target Indication Analysis: Acute Lymphoblastic Leukemia, B-Cell Lymphoma and Multiple Myeloma to Drive CAR T Cell Therapy Market Growth
According to the cancer data published by the Leukemia and Lymphoma Society in 2023, there were 59,610 new cases of leukemia, along with 89,380 new cases of lymphoma in the US. Many of the approved and clinical stage CAR T cell therapies target these hematological indications. Rising incidence and prevalence of cancer, as well as an increase in the relapse / remission rates will drive the adoption of CAR T cell therapies, driving the market growth. The developers of Idecabtagene Vicleucel (BMS) and Ciltacabtagene Autoleucel (Janssen and Legend Biotech) have published positive results from phase III trials for the treatment of multiple myeloma as earlier line of treatment compared to the currently approved status as fifth line therapies. Such developments will expand the potential market size of CAR T cell therapy market.
Regional Analysis: North America Holds the Largest Share in the Current CAR T Cell Therapy Market
Based on the regional distribution, North America held 54% market share in 2024 (in terms of revenues generated through sales of approved CAR T cell therapies). Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption.
By 2035, Europe is likely to capture more than 35% share of the global market share. In the UK, Yescarta® and Kymriah® have been to date provided through National Health Services’s (NHS) Cancer Drugs Fund, through which patients can get access to the approved drugs that have not received approval from National Institute for Health and Care Excellence (NICE) on their cost-effectiveness. However, in 2023 Yescarta (Axicabtagene Ciloleucel) became the first CAR T cell therapy to receive approval from NICE to be provided to the patients through NHS. As such, the European market will continue to grow at a healthy CAGR during the forecast period.
Market Forces Analysis: Therapy Price and Manufacturing Challenges Likely to Slow Down the CAR T Therapy Market Growth
Manufacturing biologics and cell therapies is considerably complex, as compared to small molecule drugs. The high manufacturing cost also contributes to the high price of the therapy, essentially leading to limited adoption in case of unavailability of reimbursement. In 2021, BMS faced manufacturing bottleneck for its CAR-T idecabtagene vicleucel (ABECMA®), driven by shortage of viral vectors in addition to other reasons. In 2022, Janseen and Legend Biotech rolled out their CAR-T ciltacabtagene autoleucel (CARVYKTI ®) in a phased manner in the US instead of a nationwide launch owing to manufacturing limitations.
These challenges may be temporary as the market matures and is supported by the cell therapy contract manufacturers.
Key Companies Involved in CAR T Cell Therapy Market
Examples of key CAR T cell therapy companies (the complete list of companies is available in the full report) include Alaunos Therapeutics, Autolus, Abelzeta Pharma, Bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics, Cellectis, Gilead Sciences, Innovative Cellular Therapeutics, Kuur Therapeutics, Noile-Immune Biotech, Novartis, Shanghai GeneChem, Sinobioway Cell Therapy, Takara Bio and Wellington Zhaotai Therapies. This global CAR T cell therapy market research report includes an easily searchable excel database of all the companies that are developing CAR T cell therapies.
Recent Developments in the Car T Cell Therapy Market
Several recent developments have taken place in the field of CAR T cell therapy. the analyst has outlined some of these initiatives below. These developments substantiate the overall market trends that have been outlined in the analysis.
- In February 2024, Astellas entered into a strategic agreement with Kelonia with an aim to develop CAR-T cell therapy by combining their iGPS system with later company’s ACCEL technology.
- In January 2024, China approved Inaticabtagene Autoleucel, a next generation CD19 targeting CAR-T cell therapy, for the treatment of patients suffering from relapsed or refractory B-cell acute lymphoblastic leukemia.
- In October 2023, the Central Drugs Standard Control Organization approved NexCAR19, a next generation CAR-T cell therapy, for the treatment of patients suffering from advanced lymphoma or leukemia.
Car T Cell Therapy Market Report Coverage
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this industry, across different geographies. Amongst other elements, the market report includes:
- A preface providing an introduction to the full report, CAR T Cell Therapy Market (5th Edition), industry trends and global forecasts till 2035.
- An outline of the systematic research methodology adopted to conduct the study on CAR T cell therapy, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
- An overview of economic factors that impact the overall CAR T cell therapy industry, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
- An executive summary of the key insights captured during the research, offering a high-level view on the current landscape of CAR T cell therapy market and its likely evolution in the short to mid and long term.
- A general overview of CAR T cell therapies, along with its comparison with T-cell immunotherapies. Additionally, it features the historical evolution and advancements in the manufacturing of CAR-T cell therapies. Further, it highlights the challenges faced by CAR-T cell therapy developers that are anticipated to play a crucial role in shaping the future of CAR-T cell therapies.
- A detailed assessment of the current market landscape of CAR-T cell therapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia-Pacific).
- An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to haematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
- A detailed analysis of completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
- An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
- Elaborate profiles of the several leading players in the domain of CAR T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T therapies, technology portfolio (if available), recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, the analyst has provided details of the strategic / venture capital investments made in these companies.
- An analysis of various types of partnership that have been inked between several stakeholders in the CAR T cell therapy industry, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
- An analysis of the investments that have been made into CAR T cell therapy companies that have proprietary therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
- An in-depth analysis of patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
- A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
- An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.
- An in-depth analysis of the factors that can impact the growth of CAR T cell therapy market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
- A detailed estimate of the current market size, opportunity and the future growth potential of the CAR T cell therapy market over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within this market. Further, in order to account for future uncertainties and to add robustness to the model, the analyst has provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
- Detailed projections of the current and future CAR T cell therapy market across type of target indication, such as non-Hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma).
- Detailed projections of the current and future CAR T-cell therapy market across type of target antigen, such as CD19, BCMA, CD19 / CD22 and others.
- Detailed projections of the current and future CAR T cell therapy market across leading players.
- Detailed projections of the current and future CAR T-cell therapy market across key geographical regions, such as North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World.
- A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™), Ciltacabtagene Autoleucel (CARVYKTI™) and others.
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the CAR T cell therapy market, over the forecast period. Based on multiple relevant parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period.
The CAR T cell therapy market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as target indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis, Renal Cell Carcinoma and Others), target antigens (CD19, BCMA, CD19 / CD22 and Others), key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World), key players and sales forecast. In order to account for future uncertainties and to add robustness to the model, the analyst has provided three CAR T cell therapy market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the CAR T cell therapy market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders (Arranged based on the seniority level):
- Former Chief Executive Officer, Small Company, Netherlands
- Chief Executive Officer, Founder and Chairman, Mid-sized Company, China
- Former Chief Operating Officer, Small Company, France
- Former Vice President, Large Company, US
- Former Vice President Immuno-Oncology, Small Company, Belgium
- Director Business Development, Small Company, US
- Former Competitive Intelligence Manager, Small Company, France
- Professor, Non-industry, China
- Assistant Professor, Non-industry, US
Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this CAR T cell therapy market report are in USD, unless otherwise specified.
Key Benefits of Buying this Report
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the CAR T Cell Therapy Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 920th Hospital of Joint Logistics Support Force
- AbbVie Ventures
- AbCellera
- AbCheck
- AbClon
- Abound Bio
- Abzena
- Ac?badem Atunizade Hospital
- Ac?badem Labcell
- Acibadem University
- ACROBiosystems
- AdAlta
- Adaptimmune Therapeutics
- Adicet Bio
- Adimab
- Affiliated Hospital of Jiangnan University
- Affiliated Hospital of Jiangsu University
- Affiliated Hospital to Academy of Military Medical Sciences
- Affiliated Zhongshan Hospital of Dalian University
- AffyImmune Therapeutics
- AGC Biologics
- Agreen Biotech
- AK (Suzhou) Biomedical
- Alaunos Therapeutics
- Aleta Biotherapeutics
- Alexandria Venture Investments
- Allife Medical Science and Technology
- Allogene Therapeutics
- Alpha Biopharma
- Amgen Ventures
- Anhui Anke Biotechnology
- Anhui Provincial Hospital
- Antion Biosciences
- Appia Bio
- Arbele
- Arcellx
- Astellas Pharma
- Astrazeneca
- Atara Biotherapeutics
- August Pi and Sunyer Biomedical Research Institute
- Aurora Biopharma
- Autolus
- Avencell
- Bambino Gesù Hospital and Research Institute
- Bayer
- Baylor College of Medicine
- Be The Match BioTherapies
- Beam Therapeutics
- Beijing 302 Hospital
- Beijing Biohealthcare Biotechnology
- Beijing Boren Hospital
- Beijing Cancer Hospital
- Beijing Chao Yang Hospital
- Beijing Children's Hospital
- Beijing Doing Biomedical
- Beijing GoBroad Hospital Management
- Beijing HuiNengAn Biotech
- Beijing Immunochina Medical Science & Technology
- Beijing Sanbo Brain Hospital
- Beijing Tsinghua Chang Gung Hospital
- Beike Biotechnology
- Bellicum Pharmaceuticals
- Beth Israel Deaconess Medical Center (BIDMC)
- Bio-Gene Technology
- Bioceltech Therapeutics
- BioLife Solutions
- Bionomics
- BioNTech
- Bioray Laboratories
- Biosceptre
- Bluebird Bio
- Boya Jiyin
- BoYuan RunSheng Pharma (Hangzhou)
- Bristol-Myers Squibb
- Cabaletta Bio
- Cabaret Biotech
- Calibr
- California Institute for Regenerative Medicine (CIRM)
- Cancer Prevention Research Institute of Texas
- Cancer Research Technology
- Cancer Research UK
- Carbiogene Therapeutics
- Caribou Biosciences
- Carina Biotech
- Caring Cross
- Carisma Therapeutics
- CARsgen Therapeutics
- Cartesian Therapeutics
- Cartherics
- Case Comprehensive Cancer Center
- Celgene
- Cell and Gene Therapy Catapult
- Cell Design Labs
- Cellectis
- Cellex Patient Treatment
- CELLforCURE
- CellPoint
- Cellular Biomedicine Group
- Cellvec
- Celularity
- Celyad Oncology
- Center for International Blood and Marrow Transplant Research
- Central South University
- Changhai Hospital
- Chengdu USino Technology Biology
- Children's Hospital and Health System Foundation
- Children's Hospital of Fudan University
- Children's Hospital of Philadelphia
- Children’s Hospital of Philadelphia
- China Immunotech (Beijing) Biotechnology
- China Meitan General Hospital
- China Regenerative Medicine International (CRMI)
- Chinese Academy of Sciences
- Chinese PLA General Hospital
- Chongqing Precision Biotech
- Chongqing Public Health Medical Center
- Chongqing Sidemu Biotech
- Chongqing University Cancer Hospital
- City of Hope Medical Center
- CoIMMUNE
- Cold Spring Harbor Laboratory
- Columbia University
- CRISPR Therapeutics
- Cryoport
- CureSearch for Children's Cancer
- Curocell
- CytoLumina Technologies
- CytoMed Therapeutics
- Cytovia Therapeutics
- DAIICHI SANKYO COMPANY
- Dana-Farber Cancer Institute
- Dartmouth College
- Delenex Therapeutics
- DLR German Aerospace Center
- Dongguan People's Hospital
- East Clinical Center of Oncology
- Eden BioCell
- Editas Medicine
- Eli Lilly
- Elicera Therapeutics
- Elpis Biopharmaceuticals
- Eureka Therapeutics
- Eutilex
- EXUMA Biotech
- Fate Therapeutics
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Fidelity Management & Research
- First Affiliated Hospital of Chengdu Medical College
- First Affiliated Hospital of Harbin Medical University
- First Affiliated Hospital of Wenzhou Medical Univeristy
- First Affiliated Hospital of Wenzhou Medical University
- First Affiliated Hospital of Zhejiang University
- First Affiliated Hospital Xi'an Jiaotong University
- First Hospital of Jilin University
- First People's Hospital of Foshan
- Five Prime Therapeutics
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
- Fondo Social La Caixa
- Formula Pharmaceuticals
- Fosun Pharmaceutical
- Fourth Hospital of Hebei Medical University
- Fraunhofer
- Fred Hutchinson Cancer Research
- Fred Hutchinson Cancer Research Center
- Fudan University
- Fujian Medical University
- Fundamenta Therapeutics
- FutureGen Biopharm
- G Plus Life Sciences
- GE Global Research
- GE Healthcare
- Genentech
- Genus Oncology
- Gilead Sciences
- Glycostem
- GlyTherix
- Gracell Biotechnologies
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Guangdong General Hospital
- Guangdong Zhaotai InVivo Biomedicine
- Guangzhou 8th People's Hospital
- Guangzhou Anjie Biomedical Technology
- Guangzhou First People's Hospital
- H. Lee Moffitt Cancer Center and Research Institute
- Hadassah Medical Organization
- Harvard University
- HCW Biologics
- Hebei Senlang Biotechnology
- Hebei Yanda Ludaopei Hospital
- Hefei Binhu Hospital
- Heidelberg University Hospital
- Henan Cancer Hospital
- Henan Hualong Biotechnology
- Henan Provincial People's Hospital
- Hitachi Chemical Advanced Therapeutics Solutions
- Horizon 2020
- Horizon Discovery Group
- Houston Methodist Hospital
- Hrain Biotechnology
- HuaDao (Shanghai) Biomedical
- Huai'an Second People's Hospital
- Huazhong University of Science and Technology
- Hunan Provincial People's Hospital
- Hunan Yongren Medical Innovation
- Hunan Zhaotai Yongren Biotech
- Hunan Zhaotai Yongren Medical Innovation
- IASO Biotherapeutics
- iCAR Bio Therapeutics
- iCarTAB BioMed
- iCell Gene Therapeutics
- ICON
- IIT MediTech (Jiangsu)
- ImmunoACT
- Imugene
- Inhibrx
- Innovative Cellular Therapeutics
- Innovent Biologics
- Institut Curie
- Institute of Hematology & Blood Diseases Hospital
- Institute of Hematology and Blood Transfusion
- Instituto de Salud Carlos III
- Intellia Therapeutics
- Intrexon
- Invectys
- Janssen
- Jiangsu Province Hospital of Traditional Chinese Medicine
- Jiangyin People's Hospital
- Jichi Medical University Hospital
- Jingjiang People's Hospital
- Jingzhou Central Hospital
- Jonsson Comprehensive Cancer Center
- Juno Therapeutics
- Juventas Cell Therapy
- JW Therapeutics
- KAEDI
- Karolinska Institute
- Kecellitics Biotech
- King's College London
- Kite Pharma (a Gilead Sciences Company)
- Kuur Therapeutics
- Kyverna Therapeutics
- Legend Biotech
- Leucid Bio
- Leukemia & Lymphoma Society
- Leukemia Research Foundation
- Life Technologies
- Lilly Asia Ventures
- Liminatus Pharma
- Living Pharma
- Lonza
- Loyola University Medical Center
- LUMICKS
- Lyell Immunopharma
- MabQuest
- Malaghan Institute of Medical Research
- Marino Biotechnology
- Massachusetts General Hospital
- MaSTherCell
- Max Delbrück Center for Molecular Medicine
- MaxCyte
- Mayo Clinic
- MD Anderson Cancer Center
- Medical College of Wisconsin
- MedImmune
- Medisix Therapeutics
- MediTrust Health
- Memorial Sloan Kettering Cancer Center
- Merck
- Mie University Hospital
- Miltenyi Biomedicine
- Miltenyi Biotec
- Minerva Biotechnologies
- Mink Therapeutics
- Moderna
- MolMed (acquired by AGC Biologics)
- Mustang Bio
- Nanfang Hospital of Southern Medical University
- Nanjing Bioheng Biotech
- Nanjing Children's Hospital
- NantKwest
- Nantong University
- National Cancer Center Research Institute Japan
- National Cancer Institute
- National Heart, Lung and Blood Institute
- National Institutes of Health (NIH)
- National Institutes of Health Clinical Center
- National Taiwan University Hospital
- National University Hospital, Singapore
- Navy General Hospital
- NeoStem
- Ningbo Cancer Hospital
- NIPRO
- Nkarta
- Noile-Immune Biotech
- Notch Therapeutics
- Novartis
- Novartis Venture Fund
- nSAGE
- NSF Engineering Research Center for Cell Manufacturing Technologies
- Oncodesign Biotechnology
- Oncora Medical
- OncoTracker
- Oncternal Therapeutics
- Oncyte
- ONK Therapeutics
- oNKo-innate
- ONO Pharmaceutical
- Opus Bio
- OrbiMed Advisors
- Ospedale Pediatrico Bambino Gesù (OPBG)
- Otsuka Pharmaceutical
- Ottawa Hospital Research Institute
- Outpace Bio
- Overland Pharmaceuticals
- Oxford Biomedica
- Oxford Biotherapeutics
- Oxford MEStar
- panCELLa
- Parker Institute for Cancer Immunotherapy
- Pediatric Brain Tumor Consortium
- Peking Union Medical College Hospital
- Peking University People's Hospital
- Peking University Shenzhen Hospital
- Peking University Third Hospital
- PeproMene Bio
- PersonGen BioTherapeutics
- Peter MacCallum Cancer Centre
- Pfenex
- Pfizer
- PHARMALOG Institut für klinische Forschung
- PhoreMost
- Pieris Pharmaceuticals
- Pierre Fabre
- Pinze Lifetechnology
- PLA General Hospital
- Porton Biologics
- Poseida Therapeutics
- Precigen
- Precision BioSciences
- Pregenen
- ProMab Biotechnologies
- Protheragen
- Qilu Hospital of Shandong University
- RA Capital Management
- Redmile Group
- RedoxTherapeis
- Refuge Biotechnologies
- Regeneron Pharmaceutical
- RenJi Hospital
- resTORbio
- Rockland Immunochemicals
- Roger Williams Medical Center
- Rosewell Park Comprehensive Cancer Center
- Royal Adelaide Hospital Cancer Centre
- Ruijin Hospital
- Sabz Biomedicals
- Sana Biotechnology
- Sangamo Therapeutics
- Sanofi
- Scotia Biologics
- Seattle Children's Hospital
- Seattle Children's Research Institute
- Seattle Children’s Research Institute
- Second Affiliated Hospital of Guangzhou Medical University
- Second Affiliated Hospital of Nanchang University
- Second Affiliated Hospital of Suzhou University
- Second Affiliated Hospital of Xi'an Jiaotong University
- Second Military Medical University
- Second Xiangya Hospital of Central South University
- Servier
- Shangai Cancer Institute
- Shanghai Biomed-Union Biotechnology
- Shanghai Bioray Laboratory
- Shanghai Cell Therapy Group
- Shanghai Changzheng Hospital
- Shanghai Chest Hospital
- Shanghai Children's Medical Center
- Shanghai East Hospital
- Shanghai GeneChem
- Shanghai General Hospital
- Shanghai International Medical Center
- Shanghai Jiao Tong University School of Medicine
- Shanghai Longyao Biotechnology
- Shanghai Ming Ju Biotechnology
- Shanghai OriginCell Therapeutics
- Shanghai PerHum Therapeutics
- Shanghai Pharmaceuticals
- Shanghai Public Health Clinical Center
- Shanghai Simnova Biotechnology
- Shanghai Tong Ren Hospital
- Shanghai Tongji Hospital
- Shanghai Ultra-T Immune Therapeutics
- Shanghai Unicar-Therapy Bio-medicine Technology
- Shanghai Zhongshan Hospital
- Shanxi Province Cancer Hospital
- Shariati Hospital
- Sheba Medical Center
- Shenzhen Binde Biotechnology
- Shenzhen BinDeBio
- Shenzhen Children's Hospital
- Shenzhen Geno-Immune Medical Institute
- Shenzhen Hospital of Southern Medical University
- Shenzhen Institute for Innovation and Translational Medicine
- Shenzhen Second People's Hospital
- Shenzhen University
- ShiJiaZhuang Zhongxi Children Hospital
- Shoreline Biosciences
- Sichuan Kelun-Biotech Biopharmaceutical
- Sichuan University
- Simcere Pharmaceutical
- Sinobioway Cell Therapy
- Sistema and Russian Direct Investment Fund
- Sorrento Therapeutics
- Southern Medical University
- Southwest Hospital
- SpringWorks Therapeutics
- St. Baldrick's Foundation
- St. Jude Children's Research Hospital
- Stage Cell Therapeutics
- Stand Up To Cancer
- Stanford University
- Stony Brook University
- Sun Yat-Sen University
- Syncopation Life Sciences
- T-Curx
- Takara Bio
- Takeda Pharmaceutical
- TC BioPharm
- TCRCure Biopharma
- Tehran University of Medical Sciences
- Tel Aviv Sourasky Medical Center
- Temasek
- Teneobio
- Terumo BCT
- Tessa Therapeutics
- Texas Children's Hospital
- The Affiliated Hospital Of Guizhou Medical University
- The Affiliated Hospital of Xuzhou Medical University
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- The Beijing Pregene Science and Technology
- The Children's Mercy Hospital
- The Faris Foundation
- The First Affiliated Hospital of Anhui Medical University
- The First Affiliated Hospital of Dalian Medical University
- The First Affiliated Hospital of Guangdong Pharmaceutical University
- The First Affiliated Hospital of Kunming Medical College
- The First Affiliated Hospital of Nanchang University
- The First Affiliated Hospital of Nanjing Medical University
- The First Affiliated Hospital of Soochow University
- The First Affiliated Hospital of University of Science and Technology of China
- The First Affiliated Hospital of Zhejiang University
- The First Affiliated Hospital of Zhengzhou University
- The First Affiliated Hospital with Nanjing Medical University
- The First People's Hospital of Changzhou
- The First People's Hospital of Hefei
- The First People's Hospital of Yuhang District
- The First People's Hospital of Yunnan
- The Fourth Hospital of Hebei Medical University
- The General Hospital of Western Theater Command
- The Ohio State University
- The Pregene (ShenZhen) Biotechnology
- The Second Affiliated Hospital of Chongqing Medical University
- The Second Affiliated Hospital of Hainan Medical University
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
- The Second Hospital of Anhui Medical University
- The Second Hospital of Hebei Medical University
- The Second Hospital of Nanjing Medical University
- The Seventh Affilliated Hospital
- The Sixth Affiliated Hospital of Wenzhou Medical University
- The Third People's Hospital of Kunshan
- The Wistar Institute
- ThermoFisher Scientific
- Tianjin Medical University
- Tianjin Medical University General Hospital
- Tianjin Mycure Medical Technology
- Ticaros
- Timmune Biotech
- Tiziana Life Sciences
- Tmunity Therapeutics
- Tongji Hospital
- Tongji University
- TrakCel
- Transgene
- Transposagen Biopharmaceuticals
- Tri-Service General Hospital
- TriArm Therapeutics
- Trinity College Dublin
- Triumph Over Kid Cancer Foundation
- Tsinghua University
- Twist Bioscience
- TxCell
- Ucello Therapeutics
- UCL Business
- UNC Lineberger Comprehensive Cancer Center
- Union Stem Cell & Gene Engineering
- United States Department of Defense
- University College London
- University Health Network
- University of Alberta
- University of Birmingham
- University of California
- University of Colorado
- University of Milano-Bicocca
- University of Minnesota
- University of Munich
- University of North Carolina
- University of Pennsylvania
- University of South Australia
- University of Southern California
- University of Texas
- University of Washington
- University of Washington and Seattle Cancer Care Alliance
- University of Washington Cancer Consortium
- University of Zurich
- Uppsala University
- USHEALTH
- UTC Therapeutics
- UWELL Biopharma
- V Foundation
- VCN Biosciences
- venBio
- Versant Ventures
- Vineti
- ViroMed
- Vitruvian Networks
- Vivo Capital
- Washington University
- Weill Cornell Medical College
- Weill Medical College of Cornell University
- Wellington Zhaotai Therapies
- West China Hospital
- West China Hospital of Sichuan University
- Wugen
- Wuhan Bio-Raid Biotechnology
- Wuhan Sian Medical Technology
- Wuhan Union Hospital
- WuXi AppTec
- X-Body
- Xi'An Yufan Biotechnology
- Xiangya Hospital of Central South University
- Xiangyang Central Hospital
- Xijing Hospital
- Xinhua Hospital
- Xinqiao Hospital
- Xuanwu Hospital
- Xuzhou Medical University
- Yake Biotechnology
- Yamaguchi University
- Yan'an Affiliated Hospital of Kunming Medical University
- Yunnan Cancer Hospital
- Zhejiang Provincial People's Hospital
- Zhejiang Qixin Biotech
- Zhejiang University
- Zhujiang Hospital
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 640 |
| Published | May 2024 |
| Forecast Period | 2024 - 2035 |
| Estimated Market Value ( USD | $ 4.6 Billion |
| Forecasted Market Value ( USD | $ 25 Billion |
| Compound Annual Growth Rate | 16.6% |
| Regions Covered | Global |
